New Delhi: Ranbaxy Laboratories today said it has received approval from the Health Canada to manufacture and market its generic RAN-Rosuvastatin tablets used forlowering cholesterol in the Canadian market."Ranbaxy Pharmaceuticals Canada Inc (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd has received approval from Health Canada to manufacture and marketRAN-Rosuvastatin tablets to the Canadian healthcare system," Ranbaxy Laboratories said in a statement.Health Canada is the country`s federal regulatory body of drugs and health. RAN-Rosuvastatin tablets are generic version of Astra Zeneca`s Crestor tablets.Commenting on the approval RPCI, Canada President and GM Paul Drake said: "The finished dosage form was developed, and will be manufactured within RLL`s Health Canada approved facilities located in India."
UPSC exam row: Students continue protests
Salman Khan`s Kick hits the screen
ISIS orders female genital mutilation in Iraq
Complete trial against corrupt MPs within a year: PM Modi